mRNA Capping Methods and CleanCap® Technology Benefits

Added:

Limitations of Proprietary Co-Transcriptional Capping and the Advantages of Enzymatic Capping

While CleanCap® technology offers highly efficient, streamlined co-transcriptional capping, it introduces sequence constraints and significant intellectual property barriers. CleanCap requires specific initiating nucleotides (typically a 5' AG sequence), which limits mRNA sequence design flexibility. In contrast, enzymatic capping (using Vaccinia Capping Enzyme) can cap any 5' triphosphate sequence with virtually 100% efficiency. Furthermore, CleanCap is a proprietary, patented technology. Therapeutic developers utilizing it face high licensing fees, royalty obligations, and single-source supplier risks. Enzymatic capping and emerging open-access or generic capping reagents offer a more cost-effective, flexible, and supply-chain-secure alternative for large-scale biopharma manufacturing without the associated IP bottlenecks.

Understanding of the Central Dogma of Molecular Biology, specifically how messenger RNA (mRNA) is transcribed from DNA and translated into proteins.
Familiarity with the structural anatomy of eukaryotic mRNA, including the roles of the 5' cap, 3' poly(A) tail, and untranslated regions (UTRs) in mRNA stability and translation.
Basic knowledge of the In Vitro Transcription (IVT) process, including the roles of T7 RNA polymerase, DNA templates, and nucleoside triphosphates (NTPs).
Awareness of how the innate immune system recognizes foreign RNA, particularly through pattern recognition receptors like Toll-like receptors (TLRs).
Advanced purification methods for synthetic mRNA, such as chromatography-based techniques to remove double-stranded RNA (dsRNA) and other immunogenic impurities.
The chemistry and application of Lipid Nanoparticles (LNPs) and other delivery vehicles essential for transporting capped mRNA into target cells.
Analytical methods for characterizing mRNA quality, such as liquid chromatography-mass spectrometry (LC-MS) to measure capping efficiency and integrity.
Regulatory and Good Manufacturing Practice (GMP) scale-up considerations for producing clinical-grade mRNA therapeutics and vaccines.
364 views1likes3:28@TrilinkbiotechOriginal Release: 2023-12-18

mRNA caps are protective structures at the 5' end of mRNA molecules that prevent degradation and enable protein translation; CleanCap technology provides a superior co-transcriptional capping method that produces Cap 1 mRNA structure with higher yields and efficiency compared to ARCA or enzymatic capping methods, which require separate manufacturing steps and result in lower yields, making it particularly valuable for scaling vaccine and gene therapy production.